138 related articles for article (PubMed ID: 30592585)
1. Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
Fozza C
N Engl J Med; 2018 Dec; 379(24):2379. PubMed ID: 30592585
[No Abstract] [Full Text] [Related]
2. Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
Zhu X
N Engl J Med; 2018 Dec; 379(24):2379-2380. PubMed ID: 30592586
[No Abstract] [Full Text] [Related]
3. Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
Jacoby MA; Trinkaus K; Walter MJ
N Engl J Med; 2018 Dec; 379(24):2380. PubMed ID: 30575467
[No Abstract] [Full Text] [Related]
4. Mutation Clearance after Transplantation for Myelodysplastic Syndrome.
Duncavage EJ; Jacoby MA; Chang GS; Miller CA; Edwin N; Shao J; Elliott K; Robinson J; Abel H; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Brendel K; Saba R; Wartman LD; Christopher MJ; Pusic I; Welch JS; Uy GL; Link DC; DiPersio JF; Westervelt P; Ley TJ; Trinkaus K; Graubert TA; Walter MJ
N Engl J Med; 2018 Sep; 379(11):1028-1041. PubMed ID: 30207916
[TBL] [Abstract][Full Text] [Related]
5. Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.
Ruutu T; Volin L; Beelen DW; Trenschel R; Finke J; Schnitzler M; Holowiecki J; Giebel S; Markiewicz M; Uharek L; Blau IW; Kienast J; Stelljes M; Larsson K; Zander AR; Gramatzki M; Repp R; Einsele H; Stuhler G; Baumgart J; Mylius HA; Pichlmeier U; Freund M; Casper J
Haematologica; 2011 Sep; 96(9):1344-50. PubMed ID: 21659356
[TBL] [Abstract][Full Text] [Related]
6. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.
Christopeit M; Badbaran A; Alawi M; Zabelina T; Zeck G; Wolschke C; Ayuk F; Kröger N
Eur J Haematol; 2016 Sep; 97(3):288-96. PubMed ID: 26680262
[TBL] [Abstract][Full Text] [Related]
7. [Towards a personalized pretransplantation conditioning in patients with myelodysplastic syndromes].
Goulard M; Dosquet C; Chomienne C
Med Sci (Paris); 2018 Jan; 34(1):9-11. PubMed ID: 29384085
[No Abstract] [Full Text] [Related]
8. [Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia].
Wang YX; Sun Y; Xie J; Liu N; Hu JW; Qiao ZQ; Lan SC; Zhao L; Yang Y; Li YH; Zhang B; Hu LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):522-531. PubMed ID: 37096529
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study.
Aoki K; Ishikawa T; Ishiyama K; Aoki J; Itonaga H; Fukuda T; Kakihana K; Uchida N; Ueda Y; Eto T; Mori T; Kondo T; Iwato K; Morishima Y; Tanaka J; Atsuta Y; Miyazaki Y;
Br J Haematol; 2015 Feb; 168(3):463-6. PubMed ID: 25228239
[No Abstract] [Full Text] [Related]
10. On Behalf of the SFGM-TC: Retrospective Comparison of Reduced and Higher Intensity Conditioning for High-Risk Myelodysplastic Syndrome Treated With Allogeneic Stem-Cell Transplantation.
Campidelli A; Robin M; Remen T; Luc A; Labussière-Wallet H; Dulery R; Srour M; Ceballos P; Forcade E; Nguyen-Quoc S; Furst S; Turlure P; Bay JO; Simand C; Marçais A; Daguindau E; Rubio MT; D'Aveni M
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):34-43. PubMed ID: 34456160
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic Hematopoietic Cell Transplantation Is Safe and Effective Treatment in Patients with Myelodysplastic Syndromes Seventy Years and Older.
Mukherjee S
Biol Blood Marrow Transplant; 2017 Jan; 23(1):1-2. PubMed ID: 27865911
[No Abstract] [Full Text] [Related]
12. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.
Xuan L; Dai M; Jiang E; Wang Y; Huang F; Fan Z; Xu N; Nie D; Liang X; Chen H; Ye J; Shi P; Liu H; Jin H; Lin R; Yan C; Zhang Y; Sun J; Han M; Liu Q
Lancet Haematol; 2023 Mar; 10(3):e178-e190. PubMed ID: 36702138
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
14. The role of hypomethylating agents prior to hematopoietic cell transplantation in myelodysplastic syndromes.
Sekeres MA
Best Pract Res Clin Haematol; 2018 Dec; 31(4):346-350. PubMed ID: 30466745
[TBL] [Abstract][Full Text] [Related]
15. Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome.
Festuccia M; Deeg HJ; Gooley TA; Baker K; Wood BL; Fang M; Sandmaier BM; Scott BL
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1227-1233. PubMed ID: 27064057
[TBL] [Abstract][Full Text] [Related]
16. The Art of Transplantation: Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplantation.
Ragon BK
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e71-e72. PubMed ID: 30562588
[TBL] [Abstract][Full Text] [Related]
17. [Advances on mouse transplantation model of myelodysplastic syndrome].
Fang Y; Chang CK
Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):344-347. PubMed ID: 32447943
[No Abstract] [Full Text] [Related]
18. [Advances in haploidentical hematopoietic stem cell transplantation for myelodysplastic syndromes].
Wang Y; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):348-351. PubMed ID: 28468102
[No Abstract] [Full Text] [Related]
19. Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Where Are We Going With This?
Giralt S
J Oncol Pract; 2016 Sep; 12(9):793-4. PubMed ID: 27621330
[No Abstract] [Full Text] [Related]
20. [New progress of study on hematopoietic stem cell transplantation for myelodysplastic syndromes].
Wu B; Wei Y; Zhang Q
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):510-3. PubMed ID: 22541129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
